Discrepant uptake between 111In-pentetreotide and 99mTc-MDP in bone metastases of small-cell lung cancer

Hellenic Journal of Nuclear Medicine

Volumn 12, Issue 3, 2009, Pages

  Meristoudis, Georgios ^a   Ilias, Ioannis ^b   Giannakopoulos, Vasilios ^c   Batsakis, Christos ^c   Christakopoulou, Julia ^c  

^a Henry Dynant Medical Center   (Greece)

^b E Venizelou Hospital   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MEDRONATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN;

ADULT; AGED; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; DRUG UPTAKE; HUMAN; LETTER; LUNG SMALL CELL CANCER; MALE; SKELETON; BONE TUMOR; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; SCINTISCANNING; SMALL CELL CARCINOMA;

AGED; BONE NEOPLASMS; CARCINOMA, SMALL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SOMATOSTATIN; TECHNETIUM TC 99M MEDRONATE;

EID: 72249111714     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Boundas D, Karatzas N. Nuclear medicine procedures in lung cancer imaging. Hell J Nucl Med 2004; 7: 149-157. (Pubitemid 40185991)
2. 99mTc-depreotide for the diagnosis of lung carcinoma compared to CT and the X-rays film. Hell J Nucl Med 2003; 6: 117-121.
3. Breeman WA, de Jong M, Kwekkeboom DJ et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-1429. (Pubitemid 32778689)
4. Daim VA, van Hagen PM, Krenning EP. The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis. Q J Nucl Med 2003; 47: 270-278.
5. 99mTc-(V)-dimercapto succinic acid uptake patterns, after radiation treatment. Hell J Nucl Med 2008; 11: 127-129.
6. Taylor JE, Theveniau MA, Bashirzadeh R, et al. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 1994; 15: 1229-1236.
7. Reisinger I, Bohuslavitzki KH, Brenner W et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998; 39: 224-227. (Pubitemid 28114504)
8. Tzannou IA, Karapanagiotou EM, Charpidou A et al. The use of radiolabeled somatostatin analog scintigraphy in the staging of small cell lung cancer patients. Am J Clin Oncol 2007; 30: 503-506. (Pubitemid 47537951)
9. Kwekkeboom DJ, Kho GS, Lamberts SW et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21: 1106-1111.
10. Kirsch CM, von Pawel J, Grau I, Tatsch K. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 1994; 21: 1318-1325. (Pubitemid 24371005)
11. Danielsson R, Bååth M, Svensson L et al. Imaging of regional lymph node metastases with 99mTc-depreotide in patients with lung can- cer. Eur J Nucl Med Mol Imaging 2005; 32: 925-931. (Pubitemid 41205663)
12. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. Eur J Nucl Med Mol Imaging 2004; 31: 1399-1404. (Pubitemid 39361936)
13. 99mTc-depreotide imaging. Hell J Nucl Med 2008; 11: 185-186.